A Phase 3 interventional study of JZP-110 in Narcolepsy and Obstructive Sleep Apnea, sponsored by Jazz Pharmaceuticals. Completed at 80 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-25.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.
Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 7th registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 645 is above the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 120 across the 15 interventional studies, 500 across the 3 observational. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.
Major Inclusion Criteria:
Subject meets one of the following:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once Daily Dosing
Drug: JZP-110
Change in Epworth Sleepiness Scale (ESS) Score
Change in Epworth Sleepiness Scale (ESS) score during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. This analysis included treatment group and randomization stratification factor (narcolepsy vs. OSA) as fixed effects. The ESS score at the beginning of the randomized withdrawal period was used as the covariate. The response variable was the change in ESS score from the beginning to the end of 2- week randomized withdrawal period.
Time frame: Start of randomized withdrawal phase to end of randomized withdrawal (2 weeks)
Subjects Reported as Worse on the Patient Global Impression of Change (PGIc)
Percentage of subjects reported as worse (minimally worse, much worse, or very much worse) on the PGIc during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline.
Time frame: Beginning of randomized withdrawal phase to end of the randomized withdrawal phase (2 weeks)
Subjects Reported as Worse on the Clinical Global Impression of Change (CGIc)
Subjects reported as worse (very much worse, much worse, and minimally worse) on the CGIc during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline.
Time frame: Beginning of randomized withdrawal phase to end of the randomized withdrawal phase (2 weeks)
| Milestone | JZP-110 | Placebo |
|---|---|---|
| Started | 643 | 0 |
| Completed | 458 | 0 |
| Not completed | 185 | 0 |
| Milestone | JZP-110 | Placebo |
|---|---|---|
| Started | 140 | 142 |
| Completed | 137 | 141 |
| Not completed | 3 | 1 |
Change in Epworth Sleepiness Scale (ESS) score during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. This analysis included treatment group and randomization stratification factor (narcolepsy vs. OSA) as fixed effects. The ESS score at the beginning of the randomized withdrawal period was used as the covariate. The response variable was the change in ESS score from the beginning to the end of 2- week randomized withdrawal period.
| points on a scale | JZP-110 | Placebo |
|---|---|---|
| Change in Epworth Sleepiness Scale (ESS) Score | 1.6 ± 0.41 | 5.3 ± 0.41 |
Percentage of subjects reported as worse (minimally worse, much worse, or very much worse) on the PGIc during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline.
| percentage of subjects | JZP-110 | Placebo |
|---|---|---|
| Subjects Reported as Worse on the Patient Global Impression of Change (PGIc) | 28.2 | 64.5 |
Subjects reported as worse (very much worse, much worse, and minimally worse) on the CGIc during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline.
| percentage of subjects | JZP-110 | Placebo |
|---|---|---|
| Subjects Reported as Worse on the Clinical Global Impression of Change (CGIc) | 28.7 | 63.8 |
Collected over The Safety Population consisted of all subjects who received at least 1 dose of study medication. Adverse events are reported across the entire study (e.g., the open-label and randomized withdrawal periods combined).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JZP-110 | 1/643 (0.2%) | 27/643 (4.2%) | 269/643 (41.8%) |
| Placebo | 0/142 (0%) | 0/142 (0%) | 3/142 (2.1%) |
| Event | JZP-110 | Placebo |
|---|---|---|
| Atrial fibrillationCardiac disorders | 4/643 | 0/142 |
| AgitationPsychiatric disorders | 2/643 | 0/142 |
| Hallucination, auditoryPsychiatric disorders | 2/643 | 0/142 |
| Alcohol poisoningInjury, poisoning and procedural complications | 2/643 | 0/142 |
| DizzinessNervous system disorders | 2/643 | 0/142 |
| Cluster headacheNervous system disorders | 2/643 | 0/142 |
| Abdominal painEar and labyrinth disorders | 2/643 | 0/142 |
| Deep vein thrombosisVascular disorders | 1/643 | 0/142 |
| Prostate cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/643 | 0/142 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/643 | 0/142 |
| Event | JZP-110 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 71/643 | 0/142 |
| NauseaGastrointestinal disorders | 57/643 | 1/142 |
| NasopharyngitisInfections and infestations | 54/643 | 1/142 |
| InsomniaPsychiatric disorders | 51/643 | 1/142 |
| Dry mouthGastrointestinal disorders | 47/643 | 0/142 |
| AnxietyPsychiatric disorders | 46/643 | 0/142 |
| Decreased appetiteMetabolism and nutrition disorders | 32/643 | 0/142 |
| Upper respiratory tract infectionInfections and infestations | 32/643 | 0/142 |
| Age, Continuous(years) | Open-label Period |
|---|---|
| Mean | 49.31 ± 14.155 |
| Sex: Female, Male(Participants) | Open-label Period |
|---|---|
| Female | 306 |
| Male | 337 |
| Race (NIH/OMB)(Participants) | Open-label Period |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 15 |
| Native Hawaiian or Other Pacific Islander | 3 |
| Black or African American | 109 |
| White | 506 |
| More than one race | 8 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2015, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2019, 1 year 6 months after primary completion. A results delay was requested in Dec 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solriamfetol